# US 2001/0026799 A1 · Herpes simplex virus strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026799 A1
- Document ID: US20010026799A1
- Status: Published application
- Kind: A1
- Application number: 09/829,839
- Filed: 2001-04-10
- Published: 2001-10-04
- Earliest claimed: 1997-05-22
- Inventors: Neal A. DeLuca
- Web page: https://patentgrep.com/patent/US20010026799A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides an HSV having a genome with a mutation of a TAATGARAT sequence such that, in the presence of a ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.

## Claims

### Claim 1

A herpes simlex virus (HSV) including a genome having a mutation of a TAATGARAT sequence such that, in the presence of HSV ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.

### Claim 2 (depends on 1)

The HSV of claim 1, which includes a further mutation.

### Claim 3 (depends on 2)

The HSV of claim 2, wherein the further mutation affects at least one of the ICP0, ICP22, ICP27, ICP47, ICP6, or UL41 loci.

### Claim 4 (depends on 1)

The HSV of claim 1, wherein the genome includes an exogenous gene.

### Claim 5 (depends on 2)

The HSV of claim 2, wherein the genome includes an exogenous gene.

### Claim 6 (depends on 3)

The HSV of claim 3, wherein the genome includes an exogenous gene.

### Claim 7 (depends on 4)

The HSV of claim 4, wherein the exogenous gene encodes a cytokine, cytosine deaminase, or thymadine kinase.

### Claim 8 (depends on 5)

The HSV of claim 5, wherein the exogenous gene encodes a cytokine, cytosine deaminase, or thymadine kinase.

### Claim 9 (depends on 6)

The HSV of claim 6, wherein the exogenous gene encodes a cytokine, cytosine deaminase, or thymadine kinase.

### Claim 10 (depends on 4)

A method of expressing a polynucleotide within a cell including infecting the cell with an HSV of claim 4.

### Claim 11 (depends on 5)

A method of expressing a polynucleotide within a cell including infecting the cell with an HSV of claim 5.

### Claim 12 (depends on 6)

A method of expressing a polynucleotide within a cell including infecting the cell with an HSV of claim 6.

### Claim 13 (depends on 1)

A composition for the administration of a mutant virus including an HSV of claim 1 and a pharmacologically acceptable carrier.

### Claim 14 (depends on 2)

A composition for the administration of a mutant virus including an HSV of claim 2 and a pharmacologically acceptable carrier.

### Claim 15 (depends on 3)

A composition for the administration of a mutant virus including an HSV of claim 3 and a pharmacologically acceptable carrier.

### Claim 16 (depends on 4)

A composition for the administration of a mutant virus including an HSV of claim 4 and a pharmacologically acceptable carrier.

### Claim 17 (depends on 5)

A composition for the administration of a mutant virus including an HSV of claim 5 and a pharmacologically acceptable carrier.

### Claim 18 (depends on 6)

A composition for the administration of a mutant virus including an HSV of claim 6 and a pharmacologically acceptable carrier.

### Claim 19 (depends on 7)

A composition for the administration of a mutant virus including an HSV of claim 7 and a pharmacologically acceptable carrier.
